Consolidated Statements of Cash Flows - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (106,806)	$ (36,896)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	457	422
Amortization of right-of-use asset	271	209
Accretion of discount related to marketable securities	(512)
Share-based compensation	6,223	5,332
Charge for purchase of in-process research and development assets	80,802
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(4,144)	5,071
Accounts payable	(608)	(677)
Accrued expenses and other current liabilities	614	(1,922)
Deferred revenue	15,982
Other long-term liabilities	153	(229)
Net cash used in operating activities	(7,568)	(28,690)
Cash flows from investing activities:
Purchases of marketable securities	(38,929)
Cash acquired in connection with MorphImmune merger, net of transaction costs	9,276
Purchases of property and equipment	(831)	(248)
Net cash used in investing activities	(30,484)	(248)
Cash flows from financing activities:
Payment of offering costs	(8,997)
Proceeds from PIPE transaction	125,000
Proceeds from exercise of stock options	371	32
Proceeds from issuance of common stock under ATM, net	34
Net cash provided by financing activities	116,408	32
Net increase (decrease) in cash and cash equivalents and restricted cash	78,356	(28,906)
Cash and cash equivalents and restricted cash at beginning of year	20,423	49,329
Cash and cash equivalents and restricted cash at end of year	$ 98,779	20,423
Supplemental disclosures of non-cash investing and financing activities:
Operating lease right-of-use asset and lease liability recorded upon adoption of ASC 842		$ 492
Issuance of common stock and stock-based equity awards for the MorphImmune merger	87,161
Remeasurement of operating right-of-use asset and lease liability due to lease extension	$ 226
Right-of-use asset and lease liability recognized for new operating lease liabilities	1,325
Issuance of common stock to certain board of directors in lieu of accrued compensation	221
Property and equipment included in accounts payable	$ 372